Hepion Pharmaceuticals, Inc.
Hepion Pharmaceuticals, Inc. (HEPA) is a Biotechnology company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for Hepion Pharmaceuticals, Inc. in 2026.
Earnings calendar
Next earnings date
—
Not scheduled
EPS estimate
—
Revenue estimate
—
Past earnings
No earnings history available.
Dividend calendar
No dividend history available.
Company profile
Hepion Pharmaceuticals, Inc., a U.S.-based biopharmaceutical entity, is dedicated to developing therapeutic interventions for chronic hepatic ailments. Central to their efforts is Rencofilstat, a cyclophilin inhibitor that has successfully concluded Phase 2a clinical trials. This compound operates by disrupting multiple pathological pathways implicated in the worsening of liver disease. It is currently progressing through clinical development for non-alcoholic steatohepatitis (NASH) and is additionally being explored in nonclinical research for its potential to reduce liver fibrosis and lessen hepatocellular carcinoma tumor loads in experimental models of NASH. Moreover, Rencofilstat has exhibited antiviral properties against hepatitis B, C, and D viruses through diverse mechanisms. The company, established in 2013 and situated in Edison, New Jersey, rebranded as Hepion Pharmaceuticals, Inc. in July 2019, having previously operated as ContraVir Pharmaceuticals, Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Exchange
- Nasdaq
- CEO
- Gary S. Stetz
- Employees
- 2
- IPO date
- 10 Feb 2014
- ISIN
- US4268974015
- Website
- hepionpharma.com
Frequently asked questions
Where is Hepion Pharmaceuticals, Inc. stock listed?
Hepion Pharmaceuticals, Inc. (HEPA) is listed on Nasdaq.